Acorda Therapeutics Inc. (NASDAQ:ACOR) has received a consensus recommendation of “Hold” from the nine brokerages that are currently covering the stock. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $39.40.

A number of research analysts have issued reports on ACOR shares. Leerink Swann started coverage on Acorda Therapeutics in a research note on Tuesday, October 4th. They set a “market perform” rating and a $25.00 price objective for the company. TheStreet cut Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 28th. Stifel Nicolaus reiterated a “buy” rating on shares of Acorda Therapeutics in a research note on Thursday, August 25th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Acorda Therapeutics in a research note on Thursday, August 25th. Finally, Cowen and Company restated an “outperform” rating and issued a $65.00 price target on shares of Acorda Therapeutics in a research note on Thursday, August 25th.

In related news, insider Jane Wasman sold 3,750 shares of Acorda Therapeutics stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $20.78, for a total value of $77,925.00. Following the completion of the sale, the insider now owns 105,021 shares of the company’s stock, valued at $2,182,336.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.00% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC raised its stake in Acorda Therapeutics by 14.4% in the second quarter. FMR LLC now owns 6,898,009 shares of the biopharmaceutical company’s stock valued at $175,934,000 after buying an additional 865,845 shares in the last quarter. Vanguard Group Inc. raised its stake in Acorda Therapeutics by 21.6% in the second quarter. Vanguard Group Inc. now owns 4,268,679 shares of the biopharmaceutical company’s stock valued at $108,872,000 after buying an additional 759,257 shares in the last quarter. Scopia Capital Management LP raised its stake in Acorda Therapeutics by 35.9% in the first quarter. Scopia Capital Management LP now owns 2,655,533 shares of the biopharmaceutical company’s stock valued at $70,239,000 after buying an additional 702,110 shares in the last quarter. State Street Corp raised its stake in Acorda Therapeutics by 1.6% in the second quarter. State Street Corp now owns 1,478,289 shares of the biopharmaceutical company’s stock valued at $37,707,000 after buying an additional 22,818 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Acorda Therapeutics by 14.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,346,545 shares of the biopharmaceutical company’s stock valued at $34,344,000 after buying an additional 173,635 shares in the last quarter.

Acorda Therapeutics (NASDAQ:ACOR) traded down 2.35% on Wednesday, hitting $19.11. The stock had a trading volume of 268,915 shares. Acorda Therapeutics has a 52 week low of $19.05 and a 52 week high of $43.63. The firm has a 50-day moving average of $23.72 and a 200 day moving average of $25.70. The company’s market capitalization is $880.78 million.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by $0.11. The company had revenue of $127.45 million for the quarter, compared to analysts’ expectations of $128.33 million. Acorda Therapeutics had a negative net margin of 1.08% and a positive return on equity of 1.00%. The firm’s quarterly revenue was up 12.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.31 EPS. On average, analysts predict that Acorda Therapeutics will post $0.47 earnings per share for the current year.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza.

5 Day Chart for NASDAQ:ACOR

Receive News & Stock Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related stocks with our FREE daily email newsletter.